Clinical trials: Lung Fibrosis Interstitial
Pulmonary Fibrosis, COVID-19 Pneumonia
Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19
Pulmonary fibrosis is a sequela of severe infection COVID-19.The prevalence of PCFP ranged from 2% to 45%,and the pathogenesis of PCFP has not been clearly elucidated.The ingredient of Bailing capsule is Cs-C-Q80,it has obvious…
- Trial name
- NCT05890573
- Testing
- Bailing capsule
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Idiopathic Pulmonary Fibrosis
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02171156
- Testing
- nintedanib
- Where
- 7 sites in United States
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Validation of AI-Based Detection of Idiopathic Pulmonary Fibrosis in Serial Chest Radiographs: A Retrospective Longitudinal Study
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease of unknown cause with a median survival of only 3-5 years after diagnosis.
- Trial name
- NCT07712952
- Testing
- VUNO Med-Chest X-ray
- Where
- South Korea
- Volunteers
- 175 people
- Sponsor
- Chung-Ang University Hospital
Idiopathic Pulmonary Fibrosis (IPF)
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually fatal disorder. While two anti-fibrotic drugs have been approved for treating PF of unknown cause (idiopathic pulmonary fibrosis or…
- Trial name
- STOP-IPF (NCT04598919)
- Testing
- Saracatinab
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Jewish Health
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm
- Trial name
- PICSI-H (NCT04281784)
- Testing
- EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 2,512 people
- Sponsor
- University of Washington
Lung Disease, Pulmonary Fibrosis
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in…
- Trial name
- NCT00052052
- Testing
- interferon-gamma 1b
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- InterMune
Progressive Fibrosing Interstitial Lung Disease, Lung Transplant
Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases
Lung diseases are one of the most common causes of emergency room visits. There are very few tools that are able to predict which patients will have a worsening or increasing severity of their condition.
- Conditions
- Progressive Fibrosing Interstitial Lung Disease, Lung Transplant, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT04857814
- Testing
- ADAMM- RSM Device
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Idiopathic Pulmonary Fibrosis (IPF)
Downhill Walking in IPF
In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF.
- Trial name
- NCT06756230
- Testing
- Pulmonary Rehabilitation, Downhill Walking, Treadmill Walking without incline
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Saglik Bilimleri Universitesi
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Idiopathic Pulmonary Fibrosis (IPF)
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF. The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide…
- Trial name
- NCT00162760
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Pulmonary Fibrosis
A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects
This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.
- Trial name
- NCT06939504
- Testing
- HRS-9813 Capsule, HRS-9813 Tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis
A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis.
- Trial name
- OSCILLO (NCT03898284)
- Testing
- Impulse Oscillometry
- Where
- 4 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Tours
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT06003426
- Testing
- BMS-986278
- Where
- 390 sites in United States, Argentina and 31 more
- Volunteers
- 1,255 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
This is an open label, Phase One, multicenter study, designed to evaluate the safety, tolerability, to explore the biologic effects, and to explore the clinical effects of the following doses of IW001: 0.1mg/day, 0.5 mg/day, and…
- Trial name
- NCT01199887
- Testing
- IW001
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImmuneWorks
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
University of Virginia Natural History Study
Data and specimens will be collected longitudinally from patients seen in the UVA Interstitial Lung Disease (ILD) clinic in order to describe the phenotypic expression of various interstitial lung diseases.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases
- Trial name
- NCT04896138
- Testing
- Interstitial Lung Disease
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III…
- Trial name
- NCT01619085
- Testing
- Nintedanib
- Where
- 173 sites in United States, Australia and 22 more
- Volunteers
- 752 people
- Sponsor
- Boehringer Ingelheim